• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceLIAISON XL MUREX Anti-HBc, LIAISON MUREX Control Anti-HBc
Generic NameQualitative and Quantitative Hepatitis B Virus Antibody assays
Regulation Number866.3173
ApplicantDiaSorin, Inc.
1951 Northwestern Ave.
Stillwater, MN 55082
PMA NumberP180038
Date Received09/26/2018
Decision Date01/02/2020
Reclassified Date10/20/2025
Product Code SEI 
Docket Number 20M-0107
Notice Date 01/08/2020
Advisory Committee Microbiology
Expedited Review Granted? No
Combination ProductNo
Predetermined Change Control Plan AuthorizedNo
Approval Order Statement  
Approval for the LIAISON XL MUREX Anti-HBc assay is an in vitro chemiluminescent immunoassay (CLIA) for the qualitative detection of IgG and IgM (total) antibodies to hepatitis B core antigen (anti-HBc) in human adult and pediatric serum and plasma (lithium and sodium heparin, sodium citrate and K2 EDTA) including separator tubes, on the LIAISON XL Analyzer. Assay results in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with symptoms of hepatitis or who may be at risk for HBV infection. The assay is not intended for use in screening blood, plasma or tissue donors. The LIAISON XL MUREX Control Anti-HBc (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the LIAISON XL MUREX Anti-HBc assay. The performance characteristics of LIAISON XL MUREX Control Anti-HBc have not been established for any other assays or instrument platforms.
Approval OrderApproval Order
SummarySummary of Safety and Effectiveness
LabelingLabeling
Supplements: S011 S012 S005 S013 S006 S007 S008 S009 S027 S021 S022 S002 
S003  S001 S014 S015 S010 S025 S026 S020 S023 S024 S018 
S019 S016 S017 
-
-